bonyf N.V (MLBON) Fair Value & Analysis
Healthcare · FR · Market cap €1.5M
Fair value as of: Jul 16, 2026
From 1 valuation models · updated 25 days ago
Share price −4.6% over the past month.
Below-average quality, screening 21% undervalued on our models.
What matters now
- A fairly wide model range (€2.25 to €4.49) leaves room in how you read the outcome.
- Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Price vs Fair Value (4 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 16, 2026.
How to read this chart
52‑month range €2.48 – €19.50 · fair‑value band €2.25 – €4.49 · the €2.48 price screens below the €3.01 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 16, 2026.
Analysis
bonyf N.V (MLBON) currently trades at €2.48, while our model-based Fair Value estimate is €3.01, implying the stock looks roughly 21.4% undervalued today. The Quality Score stands at 38/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low), always confirm before acting.
Trailing-twelve-month revenue stands at €309K. It earns a return on equity of -32.6%. Fundamentals as of Jul 16, 2026
Our scenario range runs from €2.25 (bear case) to €4.49 (bull case); at €2.48, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at 21%, MLBON screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 1 models by family
Notify me when MLBON reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
Figures from reported company fundamentals · as of Jul 16, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 42 · Market factors (momentum, volatility) 15
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
bonyf N.V. engages in the research, development, production, and distribution of oral and dental products in Belgium and internationally.
Full company description
bonyf N.V. engages in the research, development, production, and distribution of oral and dental products in Belgium and internationally. The company offers PerioTabs, a brushing solution for gums, teeth, and dental implants to help reduce gingivitis, periodontitis, peri-mucositis, and peri-implantitis; and AphtoFix, a film-forming cream for the local treatment of mouth ulcers. It also provides denture care products, such as OlivaFix denture adhesive creams and NitrAdine disinfecting denture tabs; Denture Repair-fix, an instant repair system for broken or cracked dentures and teeth detached from dentures; Fixobridge, a ready to use cement that fixes dislodged crowns, inlays, and bridges; denture relining cushion for ill-fitting dentures; Effervescent denture cleanser tablets; Superior denture adhesive creams; and Cavifix, a synthetic resin-based filling material to temporarily seal newly formed cavities and repair lost fillings or inlays. In addition, the company offers orthodontic care products, including NitrAdine Ortho & Junior disinfecting tabs to clean and disinfect removable orthodontic appliances; and wound care products comprising HeelFix and FingerFix paste dressing products for cracks and chapped skin on feet and hands. bonyf N.V. was incorporated in 1979 and is headquartered in Knokke-Heist, Belgium.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2019 – FY2024 · reported fiscal years
bonyf N.V reported revenue of €281K in FY2024 versus €3.2M in FY2019, a compound −38.5%/yr. Reported net income was −€36.5K in FY2024.
Watch MLBON: get an alert when its fair value changes →
Peer Group
Medical Instruments & Supplies · 203 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Instruments & Supplies median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Insider activity: 35/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 16, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $402.33 | $150.04 | -63% |
| EssilorLuxottica Société anonyme 1EL | €172.45 | €68.55 | -60% |
| Medline Inc MDLN | $41.11 | $30.15 | -27% |
| Becton, Dickinson and Company BDX | $150.65 | $103.53 | -31% |
| Alcon Inc ALC | $70.26 | $39.78 | -43% |
| ResMed Inc RMD | $203.87 | $187.89 | -8% |
| West Pharmaceutical Services, Inc WST | $353.71 | $143.97 | -59% |
| Straumann Holding STMN | CHF 106.00 | CHF 47.31 | -55% |
| Sartorius Stedim Biotech S.A DIM | €188.50 | €51.16 | -73% |
| Coloplast A/S COLOB | kr 414.00 | kr 382.22 | -8% |
Compare bonyf N.V with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is bonyf N.V (MLBON) overvalued or undervalued?
What is the fair value of MLBON?
What is the quality score of MLBON?
What is the revenue of bonyf N.V (MLBON)?
What is the net profit margin of MLBON?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track bonyf N.V and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.